(BPT) - As blood clots are the second leading cause of death in patients with cancer, a better understanding of how we can treat and prevent them is needed, particularly for a large number of the one million patients who are treating their cancer outside the hospital. Janssen Pharmaceuticals, Inc., in collaboration with Bayer HealthCare, aim to develop innovative solutions to help reduce the burden of blood clots on cancer patients.